Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic

Journal of Vascular Nursing

Volumn 35, Issue 1, 2017, Pages 27-30

  Schapkaitz, Elise ^a   Sithole, Johanna ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN; WARFARIN;

AGE; ALLELE; ATRIAL FIBRILLATION; BLOOD CLOTTING; DRUG INTERACTION; ETHNIC GROUP; ETHNOLOGY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROCEDURES; SOUTH AFRICA; THROMBOEMBOLISM;

AGE FACTORS; ALLELES; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CYTOCHROME P-450 CYP2C9; DRUG INTERACTIONS; ETHNIC GROUPS; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SOUTH AFRICA; THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 85008660675     PISSN: 10620303     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvn.2016.05.002     Document Type: Article

References (18)

1. 1 Ansell, J., Hirsh, J., Poller, L., et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:3 Suppl (2004), 204S–233S.
2. 2 Cushman, M., Booth, S.L., Possidente, C.J., et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 112:3 (2001), 572–577.
3. 3 Sconce, E.A., Khan, T.I., Wynne, H.A., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:7 (2005), 2329–2333.
4. 4 Scordo, M.G., Pengo, V., Spina, E., et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:6 (2002), 702–710.
5. 5 Limdi, N.A., Wadelius, M., Cavallari, L., et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115:18 (2010), 3827–3834.
6. 6 Scott, S.A., Edelmann, L., Kornreich, R., et al. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 82:2 (2008), 495–500.
7. 7 Lindh, J.D., Holm, L., Andersson, M.L., et al. Influence of CYP2C9 genotype on warfarin dose requirements–a systematic review and meta-analysis. Eur J Clin Pharmacol 65:4 (2009), 365–375.
8. 8 International Warfarin Pharmacogenetics C, Klein, T.E., Altman, R.B., Eriksson, N., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:8 (2009), 753–764.
9. 9 Ross, K.A., Bigham, A.W., Edwards, M., et al. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 55:9 (2010), 582–589.
10. 10 Takeuchi, F., McGinnis, R., Bourgeois, S., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet, 5(3), 2009, e1000433.
11. 11 Dandara, C., Lombard, Z., Du Plooy, I., et al. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics 12:12 (2011), 1663–1670.
12. 12 Choi, J.R., Kim, J.O., Kang, D.R., et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J Hum Genet 56:4 (2011), 290–295.
13. 13 Lam, M.P., Cheung, B.M., The pharmacogenetics of the response to warfarin in Chinese. Br J Clin Pharmacol 73:3 (2012), 340–347.
14. 14 Wadelius, M., Chen, L.Y., Lindh, J.D., et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:4 (2009), 784–792.
15. 15 Perera, M.A., Cavallari, L.H., Limdi, N.A., et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382:9894 (2013), 790–796.
16. 16 Gong, I.Y., Tirona, R.G., Schwarz, U.I., et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118:11 (2011), 3163–3171.
17. 17 Schwarz, U.I., Ritchie, M.D., Bradford, Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:10 (2008), 999–1008.
18. 18 Kamali, X., Wulasihan, M., Yang, Y.C., et al. Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang. Lipids Health Dis, 12, 2013, 149.